


Stabilis



Midazolam hydrochloride



Tradename













Benzosed	Ecuador, India, Peru, Venezuela
Buccolam	Belgium, Croatia, Denmark, France, Germany, Great Britain, Hungary, Ireland, Italy, Japan, Luxembourg, Norway, Romania, Slovenia, Spain, Sweden, Switzerland
Crismidor	Colombia
Dalam	Argentina
Dormicum	Argentina, Austria, Colombia, Ecuador, Egypt, Finland, Germany, Greece, Hungary, Iceland, Japan, Malaysia, Mexico, Morocco, Netherlands, Poland, Portugal, Romania, russian, Saudi Arabia, Slovenia, Spain, Switzerland, United Arab Emirates
Dormipron	Colombia
Dormire	Brazil, Chile, Colombia, Ecuador, Spain
Gobbizolam	Argentina, Chile, Peru
Hypnovel	Great Britain, Ireland, Morocco, New Zealand
Induson	Colombia
Lamcord	Mexico
Midanium	Morocco, Poland
Midasedan	Colombia
Relacum	Chile, Colombia, Ecuador, Mexico
Sedoz	Colombia, Peru, Venezuela
Somnocal	Mexico
Sopodorm	Poland
Zolamid	Hungary, India, Portugal, Turkey



Stability in solutions
























































































		0,03 mg/ml	4°C		72			896
		0,5 mg/ml	24-26°C		36			41
		0,5 mg/ml	39-41°C		36			41

		0,5 mg/ml	4-6°C		36				41
		0,036 mg/ml	21°C		24				350
		0,5 mg/ml	-20°C		14				2376
		0,5 mg/ml	21-25°C		14				2376
		0,5 mg/ml	7-9°C		14				2376
		0,03 mg/ml	4°C		72				896
		0,036 mg/ml	21°C		24				350
		1 mg/ml	20°C-25°C		30				399
		1 mg/ml	22°C-24°C		10				185
		1 mg/ml	4°C		30				399
		1 mg/ml	20-25°C		27				3222
		1 mg/ml	3-4°C		27				3222
		0,035 mg/ml	22°C		24				1067
		0,035 mg/ml	4°C		24				1067
		0,036 mg/ml	21°C		24				350
		0,5 mg/ml	2-6°C		30				231
		0,5 mg/ml	22°C-24°C		30				231
		1 mg/ml	20-25°C		27				3222
		1 mg/ml	3-4°C		27				3222
		1 mg/ml	-20°C		365				3989
		1 mg/ml	-20°C		365				4201
		1 mg/ml	2-8°C		365				4201
		1 mg/ml	23-25°C		90				4201
		1 mg/ml	5°C		365				3989
		2 mg/ml	30°C		10				5
		2 mg/ml	5°C		10				5
		3 mg/ml	20°C		7				401
		3 mg/ml	32°C		7				401
		0,4 mg/ml	25°C		100				4303
		5 mg/ml	24-26°C		36				41
		5 mg/ml	25°C		100				4303
		1 mg/ml	-20°C		365				3989
		1 mg/ml	-20°C		365				4201

		1 mg/ml	2-8°C		365			4201
		1 mg/ml	23-25°C		90			4201
		1 mg/ml	5°C		365			3989



Stability of mixtures

								
		2,5 mg/ml	20°C-25°C		Morphine sulfate : 2,5 & 5 mg/ml	14		1492
		0,05 & 5 mg/ml	20°C-25°C		Tirofiban : 50 µg/ml	4		1603
		1 mg/ml	20°C-25°C		Palonosetron hydrochloride : 25 µg/ml	4		1975
		0,5 mg/ml	22°C-23°C		Milrinone lactate : 0,2 mg/ml	4		813
		0,1 & 0,5 mg/ml	23°C-25°C		Fentanyl citrate : 20 & 40 µg/ml	3		225
		0,1 & 0,5 mg/ml	23°C-25°C		Morphine sulfate : 0,25 & 1 mg/ml	3		86
		0,1 & 0,5 mg/ml	25°C		Atracurium besylate : 1 & 5 mg/ml	3		865
		0,5 mg/ml	22°C		Morphine tartrate : 1 mg/ml	28		2083
		4 mg/ml	22-25°C		Methadone hydrochloride : 0.2 mg/ml	24		1506
		1,66 mg/ml	23°C		Ondansetron hydrochloride : 1,33 mg/ml	24		815
		3,6 mg/ml	25°C		Clonidine hydrochloride : 0,015 mg/ml Sufentanil citrate : 0,03 mg/ml	7		3705
		3,6 mg/ml	25°C		Clonidine hydrochloride : 0,015 mg/ml	7		3705
		3,6 mg/ml	25°C		Ketamine hydrochloride : 25 mg/ml	7		3705
		3,6 mg/ml	25°C		Sufentanil citrate : 0,03 mg/ml	7		3705
		3,6 mg/ml	25°C		Clonidine hydrochloride : 0,015 mg/ml Piritramide : 1 mg/ml Ketamine hydrochloride : 25 mg/ml Lormetazepam : 0,12 mg/ml Sufentanil citrate : 0,03 mg/ml	8		3705
		1,2 mg/ml	25°C		Propofol : 6,7 mg/ml Sufentanil citrate : 0,0033 mg/ml	24		4011
		0,9 mg/ml	25°C		Propofol : 5 mg/ml Sufentanil citrate : 0,0075 mg/ml Lormetazepam : 0,03 mg/ml	24		4011
		1,2 mg/ml	25°C		Remifentanyl hydrochloride : 1,7 µg/ml Propofol : 6,7 mg/ml	24		4011
		1,66 mg/ml	4°C		Ondansetron hydrochloride : 1,33 mg/ml	24		815
		4 mg/ml	22-25°C		Dobutamine hydrochloride : 8 mg/ml	24		1506
		0,66 & 5 mg/ml	22°C		Diamorphine hydrochloride : 0,66 & 33 mg/ml	14		1288
		0,6 mg/ml	32°C		Fentanyl citrate : 40 µg/ml Scopolamine N-butyl bromide : 0,85 mg/ml	10		1405

		0,6 mg/ml	32°C		Metoclopramide hydrochloride : 0,7 mg/ml Fentanyl citrate : 40 µg/ml	10		1405
		0,66 & 0,9 mg/ml	22°C		Fentanyl citrate : 13 & 38 µg/ml	7		929
		1 mg/ml	25°C		Famotidine : 0,4 mg/ml Hydromorphone hydrochloride : 10 mg/ml	96		2166
		0,66 & 0,9 mg/ml	38°C		Fentanyl citrate : 13 & 38 µg/ml	4		929
		1 mg/ml	4°C		Famotidine : 0,4 mg/ml Hydromorphone hydrochloride : 10 mg/ml	96		2166
		0,66 & 0,9 mg/ml	5°C		Fentanyl citrate : 13 & 38 µg/ml	7		929
		0.1 & 0.5 mg/ml	23°C		Hydromorphone hydrochloride : 2 & 20 mg/ml	23		345
		0.1 & 0.5 mg/ml	4°C		Hydromorphone hydrochloride : 2 & 20 mg/ml	23		345
		0,5 mg/ml	22°C		Morphine tartrate : 1 mg/ml Bupivacaine hydrochloride : 4 mg/ml	28		2083



Factors which affect stability

				1887
				1415
				301 939
				150 176 3466 3823
				1887
	pH > 5			186



Compatibility

	Midazolam hydrochloride : 2,5 mg/ml Alprostadil : 20 µg/ml		4651
	Midazolam hydrochloride : 2,5 mg/ml Alprostadil : 20 µg/ml		4491
	Midazolam hydrochloride : 0.05 mg/ml Aminophylline : 0.72 mg/ml		1888
	Midazolam hydrochloride : 0.25 & 0.4 mg/ml Aminophylline : 0.72 mg/ml		1888
	Midazolam hydrochloride : 10 mg/ml Amiodarone hydrochloride : 12,5 mg/ml		4119
	Midazolam hydrochloride : 1 mg/ml Amiodarone hydrochloride : 4.8 mg/ml		295
	Midazolam hydrochloride : 2.1 mg/ml Amiodarone hydrochloride : 15 mg/ml		3823























































		Midazolam hydrochloride : 1 mg/ml Amiodarone hydrochloride : 6 mg/ml		1611
		Midazolam hydrochloride : 10 mg/ml Amiodarone hydrochloride : 25 mg/ml		4119
		Midazolam hydrochloride : 10 mg/ml Amiodarone hydrochloride : 0,6 >> 9,75 mg/ml		4119
		Midazolam hydrochloride : 0.05 & 0.4 mg/ml Amoxicillin sodium : 10 mg/ml		1888
		Midazolam hydrochloride : 2 mg/ml Amphotericin B cholesteryl sulfate complex : 0,83 mg/ml		921
		Midazolam hydrochloride : 1 mg/ml Ampicillin sodium : 20 mg/ml		176
		Midazolam hydrochloride : 1 mg/ml Anidulafungin : 0.5 mg/ml		1982
		Midazolam hydrochloride : 2 mg/ml Argatroban : 1 mg/ml		1964
		Midazolam hydrochloride : 0.05 mg/ml Atracurium besylate : 0.5 mg/ml		402
		Midazolam hydrochloride : 0.1 & 0.5 mg/ml Atracurium besylate : 1 & 5 mg/ml		865
		Midazolam hydrochloride : 1 mg/ml Bivalirudin : 5 mg/ml		1713
		Midazolam hydrochloride : 1 mg/ml Blinatumomab : 0.125 & 0.375 µg/ml		3976
		Midazolam hydrochloride : 1 mg/ml Calcium gluconate : 100 mg/ml		176
		Midazolam hydrochloride : 2 mg/ml Caspofungin acetate : 0,7 mg/ml		2247
		Midazolam hydrochloride : 1 mg/ml Cefazolin sodium : 20 mg/ml		176
		Midazolam hydrochloride : 2 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Midazolam hydrochloride : 1 mg/ml Cefotaxime sodium : 20 mg/ml		176
		Midazolam hydrochloride : 2 mg/ml Ceftaroline fosamil : 2,22 mg/ml	RL	3249
		Midazolam hydrochloride : 1 mg/ml Ceftazidime : 20 mg/ml		176
		Midazolam hydrochloride : 2 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml	RL	2269
		Midazolam hydrochloride : 1 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Midazolam hydrochloride : 1 mg/ml Cefuroxime sodium : 15 mg/ml		176
		Midazolam hydrochloride : 0.05 >> 0.4 mg/ml Cefuroxime sodium : 7.5 mg/ml		1888
		Midazolam hydrochloride : 1 mg/ml Cimetidine hydrochloride : 15 mg/ml		176
		Midazolam hydrochloride : 0.2 mg/ml Ciprofloxacin lactate : 2 mg/ml		285
		Midazolam hydrochloride : 1 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299

		Midazolam hydrochloride : 2.1 mg/ml Cisatracurium besylate : 5 mg/ml		3823
		Midazolam hydrochloride : 1 mg/ml Clindamycin phosphate : 9 mg/ml		176
		Midazolam hydrochloride : 2.1 mg/ml Clonazepam : 0.2 mg/ml		3823
		Midazolam hydrochloride : 2.1 mg/ml Clonidine hydrochloride : 0.012 mg/ml		3823
		Midazolam hydrochloride : 1 mg/ml Clonidine hydrochloride : 0,018 mg/ml		2018
		Midazolam hydrochloride Daunorubicin/cytarabine liposomale : 0,4 mg/mL		4654
		Midazolam hydrochloride : 5 mg/ml Defibrotide : 8 mg/ml		3728
		Midazolam hydrochloride : 0,5 & 1,5 mg/ml Dexamethasone sodium phosphate : 0,44 & 1,33 mg/ml		1971
		Midazolam hydrochloride : 0.625 mg/ml Dexamethasone sodium phosphate : 0.5 mg/ml		1901
		Midazolam hydrochloride : 1 mg/ml Dexamethasone sodium phosphate : 4 mg/ml		176
		Midazolam hydrochloride : 0,25 mg/ml Dexamethasone sodium phosphate : 0,25 mg/ml		1637
		Midazolam hydrochloride : 2,1 mg/ml Diclofenac : 3 mg/ml		3823
		Midazolam hydrochloride : 1 mg/ml Digoxin : 100 µg/ml		176
		Midazolam hydrochloride : 1 mg/ml Dobutamine hydrochloride : 4 mg/ml		295
		Midazolam hydrochloride : 4 mg/ml Dobutamine hydrochloride : 8 mg/ml		1506
		Midazolam hydrochloride : 1 mg/ml Dobutamine hydrochloride : 2 mg/ml		176
		Midazolam hydrochloride : 4 mg/ml Dobutamine hydrochloride : 8 mg/ml		1506
		Midazolam hydrochloride : 1 mg/ml Dopamine hydrochloride : 1,6 mg/ml		176
		Midazolam hydrochloride : 1 mg/ml Dopamine hydrochloride : 3.2 mg/ml		295
		Midazolam hydrochloride : 4 mg/ml Dopamine hydrochloride : 8 mg/ml	 	1506
		Midazolam hydrochloride : 1 mg/ml Eravacycline : 0,6 mg/ml		4434
		Midazolam hydrochloride : 2.1 mg/ml Esmolol hydrochloride : 10 mg/ml		3823
		Midazolam hydrochloride : 1 mg/ml Esmolol hydrochloride : 40 mg/ml		295
		Midazolam hydrochloride : 0.15 mg/ml Famotidine : 0.2 mg/ml		398
		Midazolam hydrochloride : 1.5 mg/ml Famotidine : 2 mg/ml		215
		Midazolam hydrochloride : 1 mg/ml Fenoldopam mesylate : 80 µg/ml		1803

		Midazolam hydrochloride : 0.2 mg/ml Fentanyl citrate : 25 µg/ml		1974
		Midazolam hydrochloride : 0.1 & 0.5 mg/ml Fentanyl citrate : 20 & 40 µg/ml		225
		Midazolam hydrochloride : 1 mg/ml Fentanyl citrate : 50 µg/ml		176
		Midazolam hydrochloride : 0,66 & 0,9 mg/ml Fentanyl citrate : 13 & 38 µg/ml		929
		Midazolam hydrochloride : 5 mg/ml Fluconazole : 2 mg/ml		496
		Midazolam hydrochloride : 2 mg/ml Fosphenytoin sodium : 5 mg/ml		1419
		Midazolam hydrochloride : 1 mg/ml Furosemide : 2,5 mg/ml		4605
		Midazolam hydrochloride : 1 mg/ml Furosemide : 10 mg/ml		176
		Midazolam hydrochloride : 0.05 & 0.25 mg/ml Furosemide : 0.08 mg/ml		1888
		Midazolam hydrochloride : 2 mg/ml Furosemide : 10 mg/ml		314
		Midazolam hydrochloride : 5 mg/ml	RL	4603
		Midazolam hydrochloride Amiodarone hydrochloride		3464
		Midazolam hydrochloride : 2.5 mg/ml		3948
		Midazolam hydrochloride : 5 mg/ml Amikacin sulfate : 5 mg/ml		186
		Midazolam hydrochloride : 5 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
		Midazolam hydrochloride : 2.5 mg/ml Atropine sulfate : 0.2 mg/ml		404
		Midazolam hydrochloride : 2 mg/ml		301
		Midazolam hydrochloride : 5 mg/ml Amoxicillin sodium : 50 mg/ml		186
		Midazolam hydrochloride : 5 mg/ml Amoxicillin sodium / clavulanic acid : 20/2 mg/ml		186
		Midazolam hydrochloride : 2 mg/ml Bivalirudin : 5 mg/ml		1944
		Midazolam hydrochloride : 5 mg/ml Bumetanide : 0.5 mg/ml		186
		Midazolam hydrochloride : 5 mg/ml		939
		Midazolam hydrochloride : 0.1 & 0.5 mg/ml		232
		Midazolam hydrochloride : > 0.6 mg/ml		232
		Midazolam hydrochloride : 0.48 mg/ml		3379
		Midazolam hydrochloride : 2.5 mg/ml Buprenorphine hydrochloride : 0.15 mg/ml		404
		Midazolam hydrochloride : 1 mg/ml	NaH CO ₃	176
		Midazolam hydrochloride : 2,1 mg/ml	NaH CO ₃	3823

		Midazolam hydrochloride : 3 mg/ml	PI ¹⁴⁸	4835
		Midazolam hydrochloride	NaH CO ₃	3466
		Midazolam hydrochloride : 2.5 mg/ml Butorphanol tartrate : 1 mg/ml	∅	404
		Midazolam hydrochloride : 5 mg/ml Caffeine : 10 mg/ml	∅	3964
		Midazolam hydrochloride : 5 mg/ml	NaH CO ₃	150
		Midazolam hydrochloride : 1 mg/ml Caffeine : 10 mg/ml		4837
		Midazolam hydrochloride : 1 mg/ml Caffeine citrate : 20 mg/ml		4837
		Midazolam hydrochloride : 5 mg/ml Cefepime dihydrochloride : 125 mg/ml		2141
		Midazolam hydrochloride : 0.5 mg/ml Cefmetazole sodium : 100 mg/ml		93
		Midazolam hydrochloride : 5 mg/ml Cefotaxime sodium : 10 mg/ml	∅	186
		Midazolam hydrochloride : 2 mg/ml Ceftaroline fosamil : 2,22 mg/ml		3249
		Midazolam hydrochloride : 5 mg/ml Ceftazidime : 83.3 mg/ml		1759
		Midazolam hydrochloride : 5 mg/ml Ceftazidime : 125 mg/ml		2141
		Midazolam hydrochloride : 2 mg/ml Ceftobiprole medocaril sodium : 2 mg/ml		2269
		Midazolam hydrochloride Ceftobiprole medocaril sodium		4650
		Midazolam hydrochloride : 1.67 mg/ml Chlorpromazine hydrochloride : 16.67 mg/ml	∅	404
		Midazolam hydrochloride : 1.67 mg/ml Cimetidine hydrochloride : 100 mg/ml	∅	404
		Midazolam hydrochloride : 0.05 & 0.25 mg/ml Cimetidine hydrochloride : 0.8 mg/ml		1888
		Midazolam hydrochloride : 5 mg/ml Ciprofloxacin lactate : 2 mg/ml	∅	186
		Midazolam hydrochloride Cisatracurium besylate		3601
		Midazolam hydrochloride : 3.6 mg/ml Clonidine hydrochloride : 0.015 mg/ml		3705
		Midazolam hydrochloride : 5 mg/ml Clonidine hydrochloride : 0.015 mg/ml	∅	186
		Midazolam hydrochloride : 5 mg/ml Cloxacillin sodium : 100 mg/ml		3012
		Midazolam hydrochloride : > 0,25 mg/ml Dexamethasone sodium phosphate : > 0,25 mg/ml		1637
		Midazolam hydrochloride : 2.5 mg/ml		3948
		Midazolam hydrochloride : 5 mg/ml Co-trimoxazole : 0.8/4 mg/ml	∅	186
		Midazolam hydrochloride : 1,2 mg/ml Dexamethasone sodium phosphate : 0,2 >>0,4 mg/ml		4404

		Midazolam hydrochloride : 5 mg/ml Dexamethasone sodium phosphate : 4 mg/ml	∅	186
		Midazolam hydrochloride : 0,66 & 5 mg/ml Diamorphine hydrochloride : 0,66 & 33 mg/ml		1288
		Midazolam hydrochloride : 2 mg/ml Diltiazem hydrochloride : 1 mg/ml		314
		Midazolam hydrochloride : 25 mg/ml Dimenhydrinate : 25 mg/ml	∅	404
		Midazolam hydrochloride : 2 mg/ml		1415
		Midazolam hydrochloride : 2.5 mg/ml Diphenhydramine hydrochloride : 25 mg/ml	∅	404
		Midazolam hydrochloride Disodium glucose-1-phosphate tetrahydrate		4802
		Midazolam hydrochloride : 2 mg/ml Dobutamine hydrochloride : 4 mg/ml		314
		Midazolam hydrochloride : 2 mg/ml Dopamine hydrochloride : 3.2 mg/ml		314
		Midazolam hydrochloride : 2 mg/ml Doripenem : 5 mg/ml		2262
		Midazolam hydrochloride : 2.5 mg/ml Droperidol : 1.25 mg/ml	∅	404
		Midazolam hydrochloride : 2 mg/ml Epinephrine hydrochloride : 20 µg/ml		314
		Midazolam hydrochloride Eptifibatide		3934
		Midazolam hydrochloride : 5 mg/ml Erythromycin lactobionate : 5 mg/ml	∅	186
		Midazolam hydrochloride : 4 mg/ml Esomeprazole sodium : 0.32 mg/ml		1506
		Midazolam hydrochloride : 5 mg/ml Etomidate : 2 mg/ml	∅	319
		Midazolam hydrochloride : 5 mg/ml Fentanyl citrate : 50 µg/ml	∅	186
		Midazolam hydrochloride : 1.67 mg/ml Fentanyl citrate : 33.33 µg/ml	∅	404
		Midazolam hydrochloride : 2 mg/ml Fentanyl citrate : 50 µg/ml		314
		Midazolam hydrochloride : 5 mg/ml Flucloxacillin sodium : 50 mg/ml	∅	186
		Midazolam hydrochloride : 5 mg/ml Fluconazole : 2 mg/ml	∅	186
		Midazolam hydrochloride : 5 mg/ml Foscarnet sodium : 24 mg/ml	∅	73
		Midazolam hydrochloride : 1 mg/ml Fosfomicin : 30 mg/ml		4055
		Midazolam hydrochloride : 5 mg/ml Furosemide : 10 mg/ml	∅	186
		Midazolam hydrochloride : 2,1 mg/ml Furosemide : 10 mg/ml	∅	3134
		Midazolam hydrochloride : 1 mg/ml Furosemide : 10 mg/ml		4605

		Midazolam hydrochloride : 2,1 mg/ml Furosemide : 10 mg/ml		3823
		Midazolam hydrochloride : 2,1 mg/ml Furosemide : 10 mg/ml		3463
		Midazolam hydrochloride Furosemide		3465
		Midazolam hydrochloride Furosemide		3781
		Midazolam hydrochloride : 1 mg/ml Gentamicin sulfate : 10 mg/ml		176
		Midazolam hydrochloride : 0.05 >> 0.4 mg/ml Gentamicin sulfate : 0.8 mg/ml		1888
		Midazolam hydrochloride : 5 mg/ml Gentamicin sulfate : 3 mg/ml		186
		Midazolam hydrochloride : 1 mg/ml Glycerophosphate disodium		4332
		Midazolam hydrochloride : 2.5 mg/ml Glycopyrronium bromide : 0.1 mg/ml		404
		Midazolam hydrochloride : 1.2 mg/ml Haloperidol lactate : 0.25 >> 0.5 mg/ml		4404
		Midazolam hydrochloride : 2.1 mg/ml Haloperidol lactate : 0.5 mg/ml		3823
		Midazolam hydrochloride : 5 mg/ml Haloperidol lactate : 0.5 & 5 mg/ml		186
		Midazolam hydrochloride : 0.5 & 1.5 mg/ml Haloperidol lactate : 0.21 & 0.62 mg/ml		1971
		Midazolam hydrochloride : 0,04 & 0,08 mg/ml Haloperidol lactate : 0,12 >> 0,8 mg/ml		4366
		Midazolam hydrochloride : 1 mg/ml Heparin sodium : 208,3 UI/ml		4698
		Midazolam hydrochloride : 2.1 mg/ml Heparin sodium : 500 UI/ml		3823
		Midazolam hydrochloride : 5 mg/ml Heparin sodium : 100 UI/ml		4389
		Midazolam hydrochloride : 5 mg/ml Heparin sodium : 417 UI/ml		186
		Midazolam hydrochloride : 2 mg/ml Heparin sodium : 100 UI/ml		314
		Midazolam hydrochloride : 1 mg/ml Hetastarch : 60 mg/ml		1721
		Midazolam hydrochloride : 5 mg/ml Human albumin : 200 mg/ml		186
		Midazolam hydrochloride Hyaluronidase		3617
		Midazolam hydrochloride : 2 mg/ml Hydrocortisone sodium succinate : 1 mg/ml		4550
		Midazolam hydrochloride : 5 mg/ml Hydrocortisone sodium succinate : 50 mg/ml		186
		Midazolam hydrochloride : 1 mg/ml Hydrocortisone sodium succinate : 1 mg/ml		4550
		Midazolam hydrochloride : 0.05 & 0.25 mg/ml Hydrocortisone sodium succinate : 0.05 mg/ml		1888

		Midazolam hydrochloride : 0.2 mg/ml Hydromorphone hydrochloride : 0.5 mg/ml		1974
		Midazolam hydrochloride : 2 mg/ml Hydromorphone hydrochloride : 1 mg/ml		314
		Midazolam hydrochloride : 0.1 >> 4.5 mg/ml Hydromorphone hydrochloride : 0.5 >> 45 mg/ml		345
		Midazolam hydrochloride Hydroxocobalamin		3932
		Midazolam hydrochloride : 1.67 mg/ml Hydroxyzine dihydrochloride : 33.33 mg/ml		404
		Midazolam hydrochloride : 1 mg/ml Ibuprofen lysinate : 10 mg/ml		4419
		Midazolam hydrochloride : 5 mg/ml Ibuprofen lysinate : 10 mg/ml		4419
		Midazolam hydrochloride : 5 mg/ml Imipenem - cilastatin sodium : 5 mg/ml		186
		Midazolam hydrochloride Imipenem-Cilastatin / Relebactam		4809
		Midazolam hydrochloride : 1 mg/ml Imipenem-Cilastatin / Relebactam : 5 mg/ml		4433
		Midazolam hydrochloride : 1 mg/ml Insulin : 1 UI/ml		295
		Midazolam hydrochloride : 2.1 mg/ml Insulin : 2 UI/ml		3823
		Midazolam hydrochloride : 4 mg/ml Insulin : 1 UI/ml		1506
		Midazolam hydrochloride : 1 & 5 mg/ml Insulin aspart : 1 UI/ml		1508
		Midazolam hydrochloride : 1 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Midazolam hydrochloride : 5 mg/ml Ketamine hydrochloride : 50 mg/ml		2109
		Midazolam hydrochloride : 3.6 mg/ml Ketamine hydrochloride : 25 mg/ml		3705
		Midazolam hydrochloride : 2 mg/ml Labetalol hydrochloride : 2 mg/ml		314
		Midazolam hydrochloride : 1 mg/ml Labetalol hydrochloride : 5 mg/ml		295
		Midazolam hydrochloride : 2 mg/ml Lansoprazole : 0.55 mg/ml		1625
		Midazolam hydrochloride : 1.2 mg/ml Levomepromazine : 0.625 >> 2.5 mg/ml		4404
		Midazolam hydrochloride : 5 mg/ml Levosimendan : 2,5 mg/ml		4389
		Midazolam hydrochloride : 2 mg/ml Linezolid : 2 mg/ml		1925
		Midazolam hydrochloride : 2 mg/ml Lorazepam : 0.5 mg/ml		314
		Midazolam hydrochloride : 3.6 mg/ml Lormetazepam : 0.12 mg/ml		3705
		Midazolam hydrochloride : 1 mg/ml Meropenem : 50 mg/ml		4319

	Midazolam hydrochloride : 4 mg/ml Methadone hydrochloride : 0.2 mg/ml		1506
	Midazolam hydrochloride : 0.2 mg/ml Methadone hydrochloride : 1 mg/ml		1974
			150
	Midazolam hydrochloride : 1 mg/ml Methylprednisolone sodium succinate : 40 mg/ml		176
	Midazolam hydrochloride : 1.67 mg/ml Metoclopramide hydrochloride : 3.33 mg/ml		404
	Midazolam hydrochloride : 1.2 mg/ml Metoclopramide hydrochloride : 3 mg/ml		4404
	Midazolam hydrochloride : 0.5 & 1.5 mg/ml Metoclopramide hydrochloride : 1.11 & 3.33 mg/ml		1971
	Midazolam hydrochloride : 1 mg/ml Metronidazole : 5 mg/ml		176
	Midazolam hydrochloride : 5 mg/ml Metronidazole : 5 mg/ml		186
	Midazolam hydrochloride : 0.05 >> 0.4 mg/ml Metronidazole : 5 mg/ml		1888
			2108
	Midazolam hydrochloride : 2 mg/ml Milrinone lactate : 0.2 mg/ml		314
	Midazolam hydrochloride : 2 mg/ml Milrinone lactate : 0.8 mg/ml		813
	Midazolam hydrochloride : 1.2 mg/ml Morphine hydrochloride : 2 >> 5 mg/ml		4404
	Midazolam hydrochloride : 0.5 & 1.5 mg/ml Morphine hydrochloride : 1.68 & 5 mg/ml		1971
			1866
			1866
	Midazolam hydrochloride : 1 >> 3 mg/ml Morphine hydrochloride : 10 >> 40 mg/ml		1866
	Midazolam hydrochloride : 5 mg/ml Morphine hydrochloride : 1 mg/ml		186
	Midazolam hydrochloride : 2 mg/ml Morphine sulfate : 2 mg/ml		314
	Midazolam hydrochloride : 1 mg/ml Morphine sulfate : 1 mg/ml		295
	Midazolam hydrochloride : 2.5 mg/ml Morphine sulfate : 5 mg/ml		404
	Midazolam hydrochloride : 2,5 mg/ml Morphine sulfate : 2,5 & 5 mg/ml		1492
	Midazolam hydrochloride : 0.2 mg/ml Morphine sulfate : 1 mg/ml		1974
	Midazolam hydrochloride : 0,1 & 0,5 mg/ml Morphine sulfate : 0,25 & 1 mg/ml		86
	Midazolam hydrochloride : 5 mg/ml N-acetylcysteine : 200 mg/ml		3766

		Midazolam hydrochloride : 5 mg/ml Nafamostat : 10 mg/mL		4545
		Midazolam hydrochloride : 1 mg/ml Nafcillin sodium : 20 mg/ml		176
		Midazolam hydrochloride : 2.5 mg/ml Nalbuphine hydrochloride : 5 mg/ml		404
		Midazolam hydrochloride : 0,04 mg/ml Nalbuphine hydrochloride : 0,05 >> 0,33 mg/ml		4867
		Midazolam hydrochloride : 5 mg/ml Naloxone hydrochloride : 0.4 mg/ml		3408
		Midazolam hydrochloride : 2 mg/ml Nicardipine hydrochloride : 1 mg/ml		314
		Midazolam hydrochloride : 2.1 mg/ml Nimodipine : 0.2 mg/ml		3823
		Midazolam hydrochloride : 2.1 mg/ml Nitroglycerin : 0.2 mg/ml	 	3823
		Midazolam hydrochloride : 2 mg/ml Nitroglycerin : 0.4 mg/ml		314
		Midazolam hydrochloride : 1 mg/ml Nitroglycerin : 0.2 mg/ml		295
		Midazolam hydrochloride : 1 mg/ml Nitroglycerin : 0,2 mg/ml		176
		Midazolam hydrochloride : 1 mg/ml Nitroprusside sodium : 0,2 mg/ml		176
		Midazolam hydrochloride : 1 mg/ml Nitroprusside sodium : 0.2 mg/ml		295
		Midazolam hydrochloride : 2 mg/ml Norepinephrine bitartrate : 0.128 mg/ml		314
		Midazolam hydrochloride : 4 mg/ml Norepinephrine bitartrate : 0.32 mg/ml	 	1506
		Midazolam hydrochloride : 1 mg/ml Norepinephrine bitartrate : 0.064 mg/ml		295
		Midazolam hydrochloride : 5 mg/ml Omeprazole sodium : 4 mg/ml		186
		Midazolam hydrochloride : 2,1 mg/ml Omeprazole sodium : 1,6 mg/ml		3823
		Midazolam hydrochloride : 1.66 mg/ml Ondansetron hydrochloride : 1.33 mg/ml		815
		Midazolam hydrochloride : 1 mg/ml Oritavancin : 0.8 >>2 mg/ml		3152
		Midazolam hydrochloride : 2.9 & 3.3 mg/ml Oxycodone hydrochloride : 14.7 & 38.5 mg/ml		2900
		Midazolam hydrochloride : 2.9 & 3.3 mg/ml Oxycodone hydrochloride : 14.7 & 38.5 mg/ml		2900
		Midazolam hydrochloride : 0.8 & 2.5 mg/ml Oxycodone hydrochloride : 0.8 & 5 mg/ml		2125
		Midazolam hydrochloride : 0.8 & 2.5 mg/ml Oxycodone hydrochloride : 0.8 & 5 mg/ml		2125
		Midazolam hydrochloride : 2 mg/ml Palonosetron hydrochloride : 50 µg/ml		1975
		Midazolam hydrochloride : 0.05 mg/ml Pancuronium bromide : 0.05 mg/ml		402

		Midazolam hydrochloride : < 0.1 mg/ml Pantoprazole sodium : < 0.01 mg/ml		1902
		Midazolam hydrochloride : 0.1 mg/ml Pantoprazole sodium : 8 mg/ml		2139
		Midazolam hydrochloride Pantoprazole sodium		2090
		Midazolam hydrochloride : > 0.1 mg/ml Pantoprazole sodium : > 0.01 mg/ml		1902
		Midazolam hydrochloride : 5 mg/ml Paracetamol : 10 mg/ml		3571
		Midazolam hydrochloride : 5 mg/ml Paracetamol : 10 mg/ml		4435
		Midazolam hydrochloride : 5 mg/ml Paracetamol : 10 mg/ml		4742
		Midazolam hydrochloride : 1.67 mg/ml Pentobarbital sodium : 33.33 mg/ml		404
		Midazolam hydrochloride : 0,5 mg/ml Pentoxifyllin : 5 mg/ml		4538
		Midazolam hydrochloride : 0,12 mg/ml Pentoxifyllin : 5 mg/ml		4543
		Midazolam hydrochloride : 2.5 mg/ml Pethidine hydrochloride : 50 mg/ml		404
		Midazolam hydrochloride : 5 mg/ml Piperacillin sodium : 150 mg/ml		186
		Midazolam hydrochloride : 3.6 mg/ml Piritramide : 1 mg/ml		3705
		Midazolam hydrochloride : 1 mg/ml Plazomicin sulfate : 24 mg/ml		4145
		Midazolam hydrochloride : 5 mg/ml Potassium chloride : 1000 mEq/l		186
		Midazolam hydrochloride : 2.1 mg/ml Potassium chloride : 10 mEq/l		3823
		Midazolam hydrochloride Potassium phosphate		3781
		Midazolam hydrochloride : 1.67 mg/ml Prochlorperazine edysilate : 1.67 mg/ml		404
		Midazolam hydrochloride : 2.5 mg/ml Promethazine hydrochloride : 12.5 mg/ml		404
		Midazolam hydrochloride : 1.8 & 3.3 mg/ml Propofol : 1.8 & 10 mg/ml		4011
		Midazolam hydrochloride : 0.3 mg/ml Propofol : 18.2 mg/ml		4011
		Midazolam hydrochloride : 1 mg/ml Propofol		660
		Midazolam hydrochloride : 2 mg/ml Propofol : 10 mg/ml		300
		Midazolam hydrochloride : 5 mg/ml Propofol : 2 mg/ml		319
		Midazolam hydrochloride : 1.67 mg/ml Ranitidine hydrochloride : 16.67 mg/ml		404
		Midazolam hydrochloride : 2 mg/ml Ranitidine hydrochloride : 1 mg/ml		314

	Midazolam hydrochloride : 0.05 & 0.25 mg/ml Ranitidine hydrochloride : 0.4 mg/ml		1888
	Midazolam hydrochloride : 5 mg/ml Ranitidine hydrochloride : 0.5 mg/ml		186
	Midazolam hydrochloride : 1 mg/ml Remifentanil hydrochloride : 120 µg/ml		3294
	Midazolam hydrochloride : 1 mg/ml Remifentanil hydrochloride : 120 µg/ml		3176
	Midazolam hydrochloride : 4 mg/ml Remifentanil hydrochloride : 20 µg/ml		1506
	Midazolam hydrochloride : 1 mg/ml Remifentanil hydrochloride : 25 & 250 µg/ml		59
	Midazolam hydrochloride : 2.1 mg/ml Remifentanil hydrochloride : 100 µg/ml		3823
	Midazolam hydrochloride : 5 mg/ml Remimazolam : 5 mg/ml		4723
	Midazolam hydrochloride : 2.1 mg/ml Rocuronium bromide : 10 mg/ml		3823
	Midazolam hydrochloride : 5 mg/ml Salbutamol sulfate : 1 mg/ml		3216
	Midazolam hydrochloride : 3.33 mg/ml Scopolamine hydrobromide : 0.287 mg/ml		404
	Midazolam hydrochloride : 1.2 mg/ml Scopolamine N-butyl bromide : 3-7 mg/ml		4404
	Midazolam hydrochloride : 0.5 & 1.5 mg/ml Scopolamine N-butyl bromide : 1.68 & 5 mg/ml		1971
	Midazolam hydrochloride : 0.12 mg/ml Sildenafil citrate : 0,6 mg/ml		4845
	Midazolam hydrochloride : 0.5 mg/ml Sildenafil citrate : 0,6 mg/ml		4845
	Midazolam hydrochloride : 1 mg/ml Sildenafil citrate : 0,6 mg/ml		4845
	Midazolam hydrochloride : 0.1 & 0.5 mg/ml Sodium bicarbonate : 50 mg/ml		1888
	Midazolam hydrochloride Sodium bicarbonate		3466
	Midazolam hydrochloride : 0.1 & 0.5 mg/ml Sodium bicarbonate : 50 mg/ml		1888
	Midazolam hydrochloride : 5 mg/ml Sodium bicarbonate : 14 mg/ml		150
	Midazolam hydrochloride : 2.1 mg/ml Sodium bicarbonate : 84 mg/ml		3823
	Midazolam hydrochloride : 1 mg/ml Sodium bicarbonate : 84 mg/ml		176
	Midazolam hydrochloride : 2.1 mg/ml Sodium bicarbonate : 84 mg/ml		3212
	Midazolam hydrochloride : 3,6 mg/ml Sodium oxybate : 200 mg/ml		3705
	Midazolam hydrochloride : 3.6 mg/ml Sufentanil citrate : 0.03 mg/ml		3705
	Midazolam hydrochloride : 1 mg/ml Sufentanil citrate : 0.005 mg/ml		3294

	Midazolam hydrochloride : 5 mg/ml Sugammadex : 100 mg/ml		3372
	Midazolam hydrochloride : 1 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
	Midazolam hydrochloride : 1 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
	Midazolam hydrochloride Temocilline		4470
	Midazolam hydrochloride : 5 mg/ml Temocilline : 83.33 mg/ml		2231
	Midazolam hydrochloride : 1 mg/ml Theophylline : 1,6 mg/ml		176
	Midazolam hydrochloride : 5 mg/ml Thiopental sodium : 25 mg/ml		3767
	Midazolam hydrochloride : 2,1 mg/ml Thiopental sodium : 60 mg/ml		3823
	Midazolam hydrochloride : 2 mg/ml Thiopental sodium : 25 mg/ml		314
	Midazolam hydrochloride : 5 mg/ml Thiopental sodium : 25 mg/ml		319
	Midazolam hydrochloride : 0,05 & 5 mg/ml Tirofiban : 50 µg/ml		1603
	Midazolam hydrochloride Tirofiban		1512
	Midazolam hydrochloride : 1 mg/ml Tobramycin sulfate : 10 mg/ml		176
	Midazolam hydrochloride : 0.5 & 1.5 mg/ml Tramadol hydrochloride : 11.18 & 33.3 mg/ml		1971
	Midazolam hydrochloride Tramadol hydrochloride		3521
	Midazolam hydrochloride : 2.1 mg/ml Urapidil : 5 mg/ml		3823
	Midazolam hydrochloride : 2,1 mg/ml Valproic acid : 16 mg/ml		3823
	Midazolam hydrochloride : 2 mg/ml Valproic acid : 2 & 20 mg/ml		4428
	Midazolam hydrochloride : 5 mg/ml Vancomycin hydrochloride : 10 mg/ml		3385
	Midazolam hydrochloride : 5 mg/ml Vancomycin hydrochloride : 5 mg/ml		186
	Midazolam hydrochloride : 1 mg/ml Vancomycin hydrochloride : 5 mg/ml		176
	Midazolam hydrochloride : 5 mg/ml Vecuronium bromide : 4 mg/ml		186
	Midazolam hydrochloride : 2 mg/ml Vecuronium bromide : 1 mg/ml		314
	Midazolam hydrochloride : 0.05 mg/ml Vecuronium bromide : 0.1 mg/ml		402
	Midazolam hydrochloride : 3 mg/ml	PI ¹⁴⁸ 	4835



Route of administration



References

	Type	Publication
5	Journal	Stiles ML, Allen LV Jr, Prince SJ. Stability of deferoxamine mesylate, floxuridine, fluorouracil, hydromorphone hydrochloride, lorazepam, and midazolam hydrochloride in polypropylene infusion-pump syringes. Am J Health-Syst Pharm 1996 ; 53: 1583-1588.
41	Journal	Pramar YV, Loucas VA, El-Rachidi A. Stability of midazolam hydrochloride in syringes and IV fluids. Am J Health-Syst Pharm 1997 ; 54: 913-915.
59	Journal	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
73	Journal	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
86	Journal	Johnson CE, Bhatt-Mehta V, Mancari SC, McKown JA. Stability of midazolam hydrochloride and morphine sulfate during simulated intravenous coadministration. Am J Hosp Pharm 1994 ; 51: 2812-2815.
93	Journal	Hutchings SR, Rusho WJ, Tyler LS. Compatibility of cefmetazole sodium with commonly used drugs during Y-site delivery. Am J Health-Syst Pharm 1996 ; 53: 2185-2188.
150	Journal	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.
176	Journal	Mantong ML, Marquardt ED. Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2567-2568.
185	Journal	McMullin ST, Burns Schaiff RA, Dietzen DJ. Stability of midazolam hydrochloride in polyvinyl chloride bags under fluorescent light. Am J Health-Syst Pharm 1995 ; 52: 2018-2020.
186	Journal	Swart EL, Mooren RAG, Van Loenen AC. Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2020-2022.
215	Journal	Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426.
225	Journal	Bhatt-Mehta V, Johnson CE, Leininger N, Agarwal M. Stability of fentanyl citrate and midazolam hydrochloride during simulated intravenous coadministration. Am J Health-Syst Pharm 1995 ; 52: 511-513.
231	Journal	Hagan RL, Jacobs III LF, Pimsler M, Merritt GJ. Stability of midazolam hydrochloride in 5% dextrose injection or 0.9% sodium chloride injection over 30 days. Am J Hosp Pharm 1993 ; 50: 2379-2381.

232	Journal	Bhatt-Mehta V, Rosen DA, King RS, Marsym CJ. Stability of midazolam hydrochloride in parenteral nutrient solutions. Am J Hosp Pharm 1993 ; 50: 285-288.
285	Journal	Elmore RL, Contois ME, Kelly J, Noe A, Poirier A. Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs. Clin Ther 1996 ; 18: 246-255.
295	Journal	Yamashita SK, Walker SE, Choudhury T, Iazzetta J. Compatibility of selected critical care drugs during Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1048-1051.
299	Journal	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Journal	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Journal	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
314	Journal	Chiu MF, Schwartz ML. Visual compatibility of injectable drugs used in the intensive care unit. Am J Health-Syst Pharm 1997 ; 54: 64-65.
319	Journal	Hadzija BW, Lubarsky DA. Compatibility of etomidate, thiopental sodium, and propofol injections with drugs commonly administered during induction of anesthesia. Am J Health-Syst Pharm 1995 ; 52: 997-999.
345	Journal	Walker SE, Meinders A, Tailor H. Stability and compatibility of reconstituted sterile hydromorphone with midazolam. Can J Hosp Pharm 1996 ; 49: 290-298.
350	Journal	Martens HJ, De Goede PN, Van Loenen AC. Sorption of various drugs in polyvinyl chloride, glass, and polyethylene-lined infusion containers. Am J Hosp Pharm 1990 ; 47: 369-373.
398	Journal	Jay GT, Fanikos J, Souney PF. Visual compatibility of famotidine with commonly used critical-care medications during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1556-1557.
399	Journal	Bleasel MD, Peterson GM, Jestrinski KW. Stability of midazolam in sodium chloride infusion packs. Aust J Hosp Pharm 1993 ; 23: 260-262.
401	Journal	Peterson GM, Khoo BHC, Galloway JG, Paterson J. A preliminary study of the stability of midazolam in polypropylene syringes. Aust J Hosp Pharm 1991 ; 21: 115-118.
402	Journal	Savitsky ME. Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 820-821.
404	Journal	Forman JK, Souney PF. Visual compatibility of midazolam hydrochloride with common preoperative injectable medications. Am J Hosp Pharm 1987 ; 44: 2298-2299.
496	Journal	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.

660	Journal	Michaels MR, Stauffer GL, Haas DP. Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsion compatibility. Ann Pharmacotherapy 1996 ; 30: 228-232.
813	Journal	Akkermann SR, Zhang H, Mullins RE, Yaughn K. Stability of milrinone lactate in the presence of 29 critical care drugs and 4 IV solutions. Am J Health-Syst Pharm 1999 ; 56: 63-68.
815	Journal	Stewart JT, Warren FW, King DT, Venkateshwaran TG, Fox JL. Stability of ondansetron hydrochloride and 12 medications in plastic syringes. Am J Health-Syst Pharm 1998 ; 55: 2630-2634.
865	Journal	Bhatt-Mehta V, Hirata S. Physical compatibility and chemical stability of atracurium besylate and midazolam hydrochloride during intravenous coinfusion. Int J Pharm Compound 1998 ; 2: 79-81.
896	Journal	Bianchi C, Airaud CB, Gayte-Sorbier A. Sorption studies of dipotassium clorazepate salt (Tranxene®) and midazolam hydrochloride (Hypnovel®) in polyvinyl chloride and glass infusion containers. J Clin Pharm Ther 1992 ; 17: 223-227.
921	Journal	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
929	Journal	Wilson KM, Schneider JJ, Ravenscroft PJ. Stability of midazolam and fentanyl in infusion solutions. J Pain Symptom Manage 1998 ; 16: 52-58.
939	Journal	Gilbar PJ, Groves CF. Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection. Aust J Hosp Pharm 1994 ; 24: 167-170.
1067	Journal	Zeidler C, Dettmering D, Schrammel W, Spieteller M. Compatibility of various drugs used in intensive care medicine in polyethylene, PVC and glass infusion containers. EJHP 1999 ; 5: 106-110.
1288	Journal	Allwood MC, Brown PW, Lee M. Stability of injections containing diamorphine and midazolam in plastic syringes. Int J Pharm Pract 1994 ; 3: 57-59.
1405	Journal	Peterson GM, Miller KA, Galloway JG, Dunne PF. Compatibility and stability of fentanyl admixtures in polypropylene syringes. J Clin Pharm Ther 1998 ; 23: 67-72.
1415	Journal	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1419	Journal	Riggs RM, English BA, Webster AA, McGuire JM, Riordan JM. Fosphenytoin Y-site stability studies with lorazepam and midazolam hydrochloride. Int J Pharm Compound 1999 ; 3: 235-238.
1492	Journal	LeBelle MJ, Savard C, Gagnon A. Compatibility of morphine and midazolam or haloperidol in parenteral admixtures. Can J Hosp Pharm 1995 ; 48: 155-160.
1506	Journal	Lopez-Cabezas C, Guerrero L, Molas G, Anglada H, Soy D. Physicochemical compatibility of high concentration drugs usually Y-site administered in intensive care units. EJHP 2015 ;22:107-112.
1508	Journal	Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F. Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU. EJHP 2015 ;22:123-124.

1512	Manufacturer	Tirofiban (Aggrastat®) - Summary of Product Characteristics Beacon Pharmaceuticals Ltd 2015
1603	Journal	Bergquist PA, Manas D, Hunke WA, Reed RA. Stability and compatibility of tirofiban hydrochloride during simulated Y-site administration with other drugs. Am J Health-Syst Pharm 2001 ; 58: 1218-1223.
1611	Journal	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1625	Journal	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1637	Journal	Wong AH, Law S, Walker SE, Bowles SK. Concentration-dependant compatibility and stability of dexamethasone and midazolam. Can J Hosp Pharm 2000 ; 53: 24-31.
1713	Journal	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Journal	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1759	Journal	Servais H, Tulkens PM. Stability and compatibility of ceftazidime administered by continuous infusion to intensive care patients. Antimicrob Agents Chemother 2001 ; 45: 2643-2647.
1803	Journal	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1866	Journal	Vermeire A, Remon JP. Compatibility and stability of morphine in binary admixtures with haloperidol, midazolam, dexamethasone or methylprednisolone. Int J Pharm 1998 ; 174: 157-177.
1887	Journal	Andersin R, Tammilehto S. Photochemical decomposition of midazolam. IV . Study of pH dependant stability by high-performance liquid chromatography. Int J Pharm 1995 ; 123: 229-235.
1888	Journal	Janknegt R, Van den Berg TJ, De Jong M, Oldenhof HGJ, Steenhoek A. Compatibility study of midazolam. Ziekenhuisfarmacie 1986 ; 2: 45-48.
1901	Journal	Good PD, Schneider JJ, Ravenscroft PJ. The compatibility and stability of midazolam and dexamethasone in infusion solutions. J Pain Symptom Manage 2004 ; 27, 5: 471-475.
1902	Journal	Walker SE, Wyllie A, Law S. Physical compatibility of pantoprazole with selected medications during simulated Y-site administration. Can J Hosp Pharm 2004 ; 57, 2: 90-96.
1925	Journal	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1944	Journal	Hartman CA, Faria CE, Mago K. Visual compatibility of bivalirudin with selected drugs. Am J Health-Syst Pharm 2004 ; 61: 1774.
1964	Journal	Hartman CA, Baroletti SA, Churchill WW et al. Visual compatibility of argatroban with selected drugs. Am J Health-Syst Pharm 2002 ; 59: 1784-1785.

1971	Journal	Azuara ML, Sanchez Y, Reyes R, Barcia E. Physical compatibility and in vivo evaluation of drug mixtures for subcutaneous infusion to cancer patients in palliative care. Support Care Cancer 2001
1974	Journal	Chandler SW, Trissel LA, Weinstein SM Combined administration of opioids with selected drugs to manage pain and other cancer symptoms: initial safety screening for compatibility. J Pain Symptom Manage 1996 ; 12, 3: 168-171.
1975	Journal	Trissel LA, Xu QA. Physical and chemical stability of palonosetron hydrochloride with lorazepam and midazolam hydrochloride during simulated Y-site administration. Int J Pharm Compound 2005 ; 9, 3: 235-237.
1982	Journal	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2018	Journal	Veggeland T. Visual compatibility of clonidine with selected drugs. Am J Health-Syst Pharm 2005 ; 62: 1968-1969.
2083	Journal	La Forgia SP, Sharley NA, Burgess NG, Doecke CJ. Stability and compatibility of morphine, midazolam and bupivacaine combinations for intravenous infusion. J Pharm Pract and Res 2002 ; 32: 65-68.
2090	Journal	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2108	Journal	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2109	Journal	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2125	Journal	Gardiner PR. Compatibility of an injectable oxycodone formulation with typical diluents, syringes, tubings, infusion bags and drugs for potential co-administration. Hospital Pharmacist 2003 ; 10: 354-361.
2139	Journal	Serrurier C, Chenot ED, Vigneron J, May I, Demoré B. Assessment of injectable drug's administration in two intensive care units and determination of potential physico-chemical incompatibilities. EJHP Science 2006 ; 12,5: 96-99.
2141	Journal	Barinian N, Chanteux H, Viaene E, Servais H, Tulkens PM. Stability and compatibility study of cefepime in comparison with ceftazidime for potential administration by continuous infusion under conditions pertinent to ambulatory treatment of cystic fibrosis patients and to administration in intensive care units. J Antimicrob Chemother 2003 ; 51: 651-658.
2166	Journal	Nassr S, Dubuc MC, Lavoie P, Brazier JL. HPLC-DAD methods for studying the stability of solutions containing hydromorphone, ketorolac, haloperidol, midazolam, famotidine, metoclopramide, dimenhydrinate and scopolamine. J Liquid Chrom Rel Technol 2003 ; 26, 17: 2909-2929.
2231	Journal	de Jongh R, Hens R, Basma V, Mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388.

2247	Journal	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2262	Journal	Brammer MK, Chan P, Heatherly K, Trusley C, Kupiec TC, Trissel LA, Psathas PA, Gilmor T, Schaufelberger D. Compatibility of doripenem with other drugs during simulated Y-site administration Am J Health-Syst Pharm 2008 ; 65: 1261-1265.
2269	Journal	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
2376	Journal	de Diego M, Godoy G, Mennikent S. Chemical stability of midazolam injection by high performance liquid chromatography. J Sep Sci 2007 ; 30, 12: 1233-1238.
2900	Journal	Hines S, Pleasance S. Compatibility of an injectable high strength oxycodone formulation with typical diluents, syringes, tubings, infusion bags and drugs for potential co-administration. EJHP 2009 ; 15, 5: 32-38.
3012	Journal	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3134	Journal	Perez Jua En, Maqueda Palau M, Arévalo Rubert Mt, Ribas Nicolau B, Amoros Cerdà SM. Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua. Enferm Intensiva 2010 ; 21: 96-103.
3152	Journal	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3176	Poster	Humbert Delaloye V, Berger M, Voirol P, Pannatier A. Compatibilité du Remifentanil avec d'autres médicaments injectables : influence du soluté. 16èmes JFSPH, Sion, 18-19 novembre 2010
3212	Journal	Ribas Nicolau, B.; P?rez Juan, E.; Amor?s Cerd?, S.M.; Ar?valo Rubert, M.J.; Maqueda Palau, M. Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos. Enferm Intensiva 2011 ;22:78-82.
3216	Journal	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3222	Journal	Karlage K, Earhart Z, Green-Boesen K, . Myrdal PB Stability of midazolam hydrochloride injection 1-mg/mL solutions in polyvinyl chloride and polyolefin bags Am J Health-Syst Pharm 2011 ;68:1537-1540.
3249	Journal	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3294	Journal	Humbert-Delaloye V, Berger M, Voirol P, Pannatier A. In vitro compatibility of remifentanil hydrochloride and sufentanil citrate with selected drugs EJHP 2012 ; 19: 57-64.
3372	Journal	Hanci V, Ali Kiraz H, Ömür D, Ekin S, Uyan B, Yurtlu B.S. Precipitation in Gallipoli: Sugammadex / Amiodarone & Sugammadex / Dobutamine & Sugammadex / Protamine. Rev Bras Anesthesiol 2013 ; 63, 1: 163-166.
3379	Journal	Fox L.M, Wilder A.G, Foushee J.A. Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration. Am J Health-Syst Pharm 2013 ;70:520-524.

3385	Journal	Raverdi V, Ampe E, Hecq JD, Tulkens PM. Stability and compatibility of vancomycin for administration by continuous infusion. J Antimicrob Chemother 2013 ; 68: 1179-1182.
3408	Journal	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3463	Journal	Eva Perez Juan, Maria Jos? Arévalo Rubert , Silvia Monica Amoros Cerda , Palau M.M, Nicolau B.R. Fármacos en perfusión continua en la unidad de cuidados intensivos: estudio de compatibilidad. Nursing 2011 ; 29 :62-6
3464	Journal	Monica Maqueda-Palau, Eva Pérez-Juan, Maria Josep Arévalo-Rubert, Sylvia Monica Amoros-Cerda, Bàrbara Ribas-Nicolau. Compatibilidad física de la amiodarona en perfusión continua Enferm Clin 2011 21:25-29.
3465	Journal	E. P?rez Juan, M. Maqueda Palau, M. Ar?valo Rubert, B. Ribas Nicolau, S.M. Amor?s Cerd?. Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua. Enferm Intensiva 2010 ;21:96-103.
3466	Journal	B. Ribas Nicolau, E. P?rez Juan, S.M. Amor?s Cerd?, M.J. Ar?valo Rubert, M. Maqueda Palau. Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos Enferm Intensiva 2011 ;22:78-82.
3521	Manufacturer	Tramadol® - Summary of Product Characteristics. Beacon Pharmaceuticals 2012
3571	Journal	Anderson C, Boehme S, Ouellette J, Stidham C, MacKay M. Physical and Chemical Compatibility of Injectable Acetaminophen During Simulated Y-Site Administration. Hosp Pharm 2014 ; 49, 1: 42-47.
3601	Manufacturer	Cisatracurium Actavis - Résumé des Caractéristiques du Produit Actavis 2012
3617	Manufacturer	Hyaluronidase (Hyalase®) - Summary of Product Characteristics Wockhardt 2011
3705	Journal	Knudsen L, Eisend S, Haake N, Kunze T. Physicochemical compatibility of commonly used analgesics and sedatives in the intensive care medicine. EJHP 2014 ;21:161-166
3728	Journal	Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3766	Journal	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	Journal	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3781	Journal	Humbert-Delaloye V, Berger-Gryllaki M, Voirol P, Testa B, Pannatier A Screening for physicochemical incompatibilities of intravenous drugs in intensive care units: the case of monobasic potassium phosphate and furosemide. EJHP 2015 ;22:1 56-58
3823	Journal	Juan E.P, Palau M.M, Cerd? S.A, Rubert M.A, Nicolau B.R. Compatibilité physique de médicaments administrés dans l'unité de soins intensifs Pharmactuel 2015 ; 48, 3 : 146-152.
3824	Journal	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98

3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3932	Manufacturer	Hydroxocobalamine (Cyanokit®) - Résumé des caractéristiques du produit Serb Laboratoire 2015
3934	Manufacturer	Eptifibatide (Integrilin®) - Résumé des caractéristiques du produit GlaxoSmithKline Laboratoire 2016
3948	Journal	Bouchoud L, Fonzo-Christe C, Klingmüller M, Bonnabry P . Compatibility of Intravenous Medications With Parenteral Nutrition - In Vitro Evaluation. JPEN 2012 ;30. 416-424.
3964	Journal	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
3976	Journal	Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B. Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
3989	Journal	Feutry F, Genay S, Velghe C, Barthélémy C, Décaudin B, Odou, P. Stability of midazolam and noradrenaline stored in cyclic olefin copolymer AT-Closed Vials® and polypropylene syringes during 365 days. Pharmaceutical Technology in Hospital Pharmacy 2017 ; 2,1: 35
4011	Journal	Gersonde F, Eisend S, Haake N, Kunze T. Physicochemical compatibility and emulsion stability of propofol with commonly used analgesics and sedatives in an intensive care unit. EJHP 2016 2016;0:1-11
4055	Journal	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4119	Poster	Marcoz N, Ing H, Sautter AM, Saadi JF, Roulin JF, Bonnabry P. Stabilité et compatibilité de solutions injectables d'amiodarone (Cordarone®) Hôpitaux Universitaire de Genève 2004
4145	Journal	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4201	Journal	Gilliot S, Masse M, Feutry F, Barthélémy C, Décaudin B, Genay S, Odou P. Long-term stability of ready-to-use 1-mg/mL midazolam solution. Am J Health-Syst Pharm 2020 ; 77, 9: 681-689.
4303	Journal	Anderson C, MacKay M. Stability of Fentanyl Citrate, Hydromorphone Hydrochloride, Ketamine Hydrochloride, Midazolam, Morphine Sulfate, and Pentobarbital Sodium in Polypropylene Syringes. Pharmacy 2015 3, 379-385.
4319	Journal	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4332	Poster	Compatibilité de Glycophos® avec d'autres médicaments administrés en perfusion aux soins intensifs (SI) Compatibilité de Glycophos® avec d'autres médicaments administrés en perfusion aux soins intensifs (SI). JFSPH 2019 2019


4366	Journal	Estan-Cerezo G, Rodriguez-Lucena F.J, Matoses Chirivella C, Jiminez-Pulido I, Garcia-Monsalve A, Navarro-Ruiz A. Midazolam and haloperidol for palliative sedation: physicochemical stability and compatibility of parenteral admixtures. Braz J Pharm Sci 2019 ;55:e17351
4389	Journal	Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G. Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, le lévamisendan et la kétamine. Pharmactuel 2019 ;52,4:206-213
4404	Poster	Müller U, Haller F, Wiedemeier P, Steuer C. Compatibility studies of seven commonly used drugs for parenteral administration in palliative care. JFSPH 2019 2019
4419	Journal	Holt R.J, Siegert S.W.K, Krishna A. Physical Compatibility of Ibuprofen Lysine Injection with Selected Drugs During Simulated Y-site Injection. J Pediatr Pharmacol Ther 2008 ; 13, 3: 155-161.
4428	Journal	Rashed S.M, Sweatman T.W, Thoma L, Hovinga C.A, Phelps S.J. Chemical Compatibility of Depacon® with Medications Frequently Administered by Intravenous Y-Site Delivery in Patients with Epilepsy or Head Trauma. J Pediatr Pharmacol Ther 2004 ; 9, 2: 126-132.
4433	Journal	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4434	Journal	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4435	Journal	Hanifah S, Nugroho B.H, Chabib L. Compatibility of acetaminophen with central nervous system medications during simulated Y-site injection. Anaesthesiol Intensive Ther 2020 ; 52, 1: 23-27.
4470	Journal	Claeysoone K, Basma V, Hens R, Van Bambeke F, de Jongh R, Tulkens P. Continuous versus intermittent infusion of temocillin in intensive care unit patient. Critical care 2005 ; 9(Suppl 1) P37
4491	Journal	De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pilar P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pediatr 2020
4528	Journal	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4538	Journal	Campbell A, Petrovski M, Senarathna G, Mukadam ,Strunk T, Batty K. Compatibility of pentoxifylline and parenteral medications. Archives of Disease in Childhood 2020 ; 105: 395-397.
4543	Journal	Senarathna G, Strunk T, Petrovski M, Batty K. Physical compatibility of pentoxifylline and intravenous medications. Archives of Disease in Childhood 2018 ;104:292–295.
4545	Journal	Kondo M, Nagano M, Yoshida M, Yoshida N, Tagui N, Yoshida M, Sugaya K, Takase H. Physical compatibility of nafamostat with analgesics, sedatives, and muscle relaxants for coronavirus disease treatment. Journal of Nippon Medical school 2021
4550	Journal	Semark, A.J, Venkatesh, K, McWhinney B.C, Pretorius, C, Roberts, J.A, Cohen J, Venkatesh B. The compatibility of a low concentration of hydrocortisone sodium succinate with selected drugs during a simulated Y-site administration. Crit Care Resusc 2013 ;15, 1: 63–66.

4603	Journal	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4605	Journal	Foinard A, Décaudin B, Barthélémy C, Debaene B, Odou P. Impact of physical incompatibility on drug mass flow rates: example of furosemide-midazolam incompatibility. Ann Allergy 2012 ; 2:28.
4650	Manufacturer	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4651	Journal	De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pascual P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pedia 2021 ;180,1169–1176.
4654	Poster	Sicard G, Donnette M, Martin N, Gensollen S, Pourroy B, Fanciullino R. Compatibilité visuelle du Vyxeos® lors d'administration en Y avec une sélection de médicaments injectables. Communication personnelle 2021
4698	Journal	Ayari G, Huart E, Vigneron J, Demoré B. Y-site compatibility of intravenous medications commonly used in intensive care units : laboratory tests on 75 mixtures involving nine main drugs. Pharmaceutical Technology in Hospital Pharmacy 2022
4723	Journal	Kondo M, Yoshida N, Yoshida M, Tanaka C, Tagami T, Horik K, Sugaya K, Takase H Physical compatibility of remimazolam with opioid analgesics, sedatives, and muscle relaxants during simulated Y-site administration. Am J Health-Syst Pharm 2022 https://doi.org/10.1093/a
4742	Journal	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4801	Journal	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:
4802	Manufacturer	Glucose-1-Phosphate disodique tétrahydraté (Phocytan®) - Résumé des caractéristiques du produit Aguettant Laboratory 2021
4809	Manufacturer	Recarbrio® - Résumé des caractéristiques du produit 2024
4835	Journal	Hammond S, Wignell A, Cooling P, Barrett D.A, Davies P. Plasma-Lyte 148 and Plasma-Lyte 148 + 5% glucose compatibility with commonly used critical care drugs. Intensive Care Medecine Experimental 2020 8:25.
4837	Journal	De Silva, D.T.N Petrovski M, Strunk T, Mukadam N, Page Sharp N, Moore B.R, Batty K.T. Physicochemical compatibility of caffeine citrate and caffeine base injections with parenteral medications used in neonatal intensive care settings. Eur J Clin Pharmacol 2024 ; 80:1079–1087.
4845	Journal	De Silva D.T.N, Strunk T, Petrovski M, Page-Sharp M, Moore B.R, Batty K.T. The Physicochemical Compatibility of Sildenafil Injection with Parenteral Medications Used in Neonatal Intensive Care Settings. Pharmaceutics 2024 ;1 6, 419.
4867	Poster	Dazan D, Aït Taleb S, Laroyenne N, Hamam Y, Conreur L, Paoli-Lombardo R, Primas N, Lamy E, Castera-Ducros C, Curti C et al. Etude des compatibilités entre la nalbuphine et d'autres principes actifs pour optimiser leur administration en service de pédiatrie. CSH (SNPHPU) Congress sept 2024 2024

Stabilis






























Midazolam hydrochloride



Stability of pharmaceutical preparations

		150 mg Dormicum® Nipagin® 60 mg Nipasol® 120 mg Simple syrup >> 60 mL	-15°C		60			3488
		150 mg Dormicum® Nipagin® 60 mg Nipasol® 120 mg Simple syrup >> 60 mL	2-8°C		60			3488
		45 mg Versed® Syrpalta® >> 18 ml	20°C		56			2499
		150 mg Dormicum® Nipagin® 60 mg Nipasol® 120 mg Simple syrup >> 60 mL	25°C		60			3488
		75 mg (5 mg/ml) ®=? Simple syrup 14.5 ml Peppermint oil 0.5 ml	25°C		14			2772
		90 mg (5 mg/ml) ®=? Simple syrup 11.4 ml Peppermint oil 0,6 ml	25°C		14			2772
		45 mg Versed® Syrpalta® >> 18 ml	40°C		56			2499

		45 mg Versed®	Syrpalta® >> 18 ml	4°C		56			2499
		150 mg Dormicum®	Nipagin® 60 mg Nipasol® 120 mg Simple syrup >> 60 mL	-15°C		60			3488
5 mg/mL - 10 mL		® = ? (APP Pharmaceuticals)	Purified water 15 mL SyrSpend SF® >> 50 mL	2-8°C		58			3437
5 mg/mL - 10 mL		® = ? (APP Pharmaceuticals)	Purified water 15 mL SyrSpend SF Cherry® >> 50 mL	2-8°C		58			3437
		150 mg Dormicum®	Nipagin® 60 mg Nipasol® 120 mg Simple syrup >> 60 mL	2-8°C		60			3488
		500mg Versed®	Simple syrup 50ml Orange dye 0,12ml Red dye Yellow dye Distilled water >>100ml	23°C		102			2575
5 mg/mL - 10 mL		® = ? (APP Pharmaceuticals)	Purified water 15 mL SyrSpend SF Cherry® >> 50 mL	25°C		58			3437
5 mg/mL - 10 mL		® = ? (APP Pharmaceuticals)	Purified water 15 mL SyrSpend SF® >> 50 mL	25°C		58			3437
		150 mg Dormicum®	Nipagin® 60 mg Nipasol® 120 mg Simple syrup >> 60 mL	25°C		60			3488




References

	Type	Publication
2499	Journal	Steedman SL, Koonce, JR, Wynn JE, Brahen NH. Stability of midazolam hydrochloride in a flavored, dye-free oral solution Am J Hosp Pharm 1992 ; 49: 615-618.
2575	Journal	Walker SE, Grad HA, Haas DA, Mayer A. Stability of parenteral midazolam in an oral formulation. Anesth Prog 1997 ; 44, 1: 17-22.
2772	Journal	Gragory DF, Koestner JA, Tobias JD. Stability of midazolam prepared for oral administration South Med J 1993 ; 86: 771-772.
3437	Journal	Geiger C.M, Sorenson B, Whaley P.A. Stability of Midazolam in SyrSpend SF and SyrSpend SF Cherry. Int J Pharm Compound 2013 ; 17, 4: 344-346.
3488	Journal	Caldes R, Ciges S.M, Borrás E, Calvelo R, Lisart F. Jarabe de midazolam: Estudio de estabilidad de una solución oral para uso hospitalario. Farm Hosp 1995 ; 19, 1: 41-44.

Stabilis



Midazolam hydrochloride



Stability of pharmaceutical preparations

?		1 mg @ = ?	microcrystalline cellulose 100 mg	22-25°C		365		4520












































































References

Type	Publication
4520 Journal	Boivin P-N, Legendre P, Bonnaure A-C, M-A. Physicochemical stability of compounded midazolam capsules over a one-year storage period. Pharmaceutical Technology in Hospital Pharmacy 2020



Dictionary

 Anxiolytic	 injection
 Tradename	 Stability in solutions
 Container	 Molecule
 Concentration	 Temperature
 Storage	 Duration of stability
 Biosimilar	 conflicting data
 References	 Glass
 NaCl 0,9% or Glucose 5%	 Protect from light
 Hour	 Day
 Sodium chloride 0,9%	 Glucose 5%
 With or without light	 Polyvinyl chloride
 Polyethylene	 Polyolefine
 Polypropylen Syringe	 Not specified
 Light	 None
 AT-Closed vial®	 Stability of mixtures
 Solvent	 Compound
 Polypropylene	 Water for Injection
 Not specified	 Factors which affect stability
 Induces	 Degradation
 Parenteral nutrition (with lipids)	 Parenteral nutrition (binary mixture)
 NaHCO ₃	 Reduction
 Enhanced stability	 Precipitation
 Compatibility	 Compatible
 Immediate precipitation	 Incompatible
 Immediate turbidity	RL Ringer's lactate solution
 Turbidity in one hour	 Precipitation after 8 hours
 Precipitation after 2 hours	 Unspecified incompatibility
 Chemical instability	 Color change
 Plasmalyte 148 (Baxter)	 Color change after 24 hours
 Immediate instability of the emulsion	 Production of gas bubbles

 specific solvent	 Turbidity in 24 hours
 Subvisual incompatibility	 Instability of the emulsion after 6 hours
 Precipitation after 15 minutes	 Plasmalyte 148 dextrose 5% (Baxter)
 Route of administration	 Intravenous
 Continuous infusion	 Intramuscular
 Subcutaneous	 Continuous subcutaneous infusion
 References	 Oral solution
 Stability of pharmaceutical preparations	 Origine
 excipient	 Medicine bottle for injection
 plastic bottle	 Capsule
 powder	 Dictionary